Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients
Andrew J Yee, Noopur S RajeDivision of Hematology-Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USAAbstract: Bone loss is a common side effect of cancer treatments, especially antihormonal treatments used in the treatment of breast and prostate cancer. Denosumab is a monoclonal...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2012
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/e634a06fd60f46699b3fc6394d02c27f |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Sea el primero en dejar un comentario!